Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.61 per share, missing the Zacks Consensus Estimate of $1.66 per share. This compares to earnings of $1.34 per share a year ago.

Featured here, the Balance Sheet for Vivos Therapeutics Inc, which summarises the company's financial position including assets, liabilities and shareholder equity for each of the latest 10 period ...

AbbVie aims to best those drugs through its acquisition of Aliada Therapeutics, a biotech whose technology enables large molecules such as antibodies to cross this protective barrier. AbbVie ...

Oppenheimer analyst Jay Olson maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) today and set a price target of $70.00. The company’s shares closed yesterday at $15.85.

Viking Therapeutics (NASDAQ:VKTX) added ~18% on Thursday to reach a five-month high as Wall Street focused on updates on its obesity candidate VK2735, even as the company posted better-than ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

Richland WA N, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. Certifies new clinic for IsoPet therapy. NorthStar Vets - Veterinary Emergency & Trauma Specialty Center in ...